Translate
Arabic
Chinese (Simplified)
Dutch
English
French
German
Italian
Portuguese
Russian
SpanishChina-Based WuXi Biologics Selects Cranbury, New Jersey for Third U.S. Clinical Manufacturing Campus
June 10, 2020
WuXi Biologics, a China-based global company with leading open-access biologics technology platforms, signed a 10-year lease for a clinical manufacturing facility in Cranbury, New Jersey.
This news follows WuXi Biologics’ recent purchase of land to build a new 107,000-square-foot clinical and commercial manufacturing facility in Worcester, Massachusetts, and the lease of a 33,000-square-foot site to establish a process development lab in King of Prussia, Pennsylvania.
According to company officials, the New Jersey clinical manufacturing facility will include 6000 L bioreactors, Process Development, Quality Control labs, along with supporting functions. The 66,000-square-foot facility is expected to become operational in late 2020 and will bring in up to 100 jobs to the region.
“We are excited to announce our third site in the United States and proud to become a member of the New Jersey community. Cranbury is a growing hub for the biotech and biopharma industries and we look forward to working with and serving our partners in the area to benefit patients worldwide,” said Dr. Chris Chen, CEO of WuXi Biologics.
WuXi Biologics, a Hong Kong-listed company, noted it is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing.